Phase 1b end-of-study results for KSI-101

The results of a phase 1b study that evaluated a potential new treatment for macular edema associated with inflammation, KSI-101 (Kodiak Sciences, Inc.), were reported at the recent Angiogenesis, Exudation, and Degeneration 2026 at the Bascom Palmer Eye Institute, Miami. Sumit Sharma, MD, described the phase 1b end-of-study results at Angiogenesis, Exudation, and Degeneration 2026 at the Bascom Palmer Eye Institute, Miami. He is a retina and uveitis specialist at the Cole Eye Institute and serves as Vice Chair for Clinical Outcomes and Safety, Quality, and Patient Experience at Cleveland Clinic, Cleveland.